01/06
Headlines

SYN

Top Stories: Chimera Investment (NYSE:CIM), Synthetic Biologics (NYSEMKT: SYN), SunTrust Banks (NYSE:STI), American Lorain Corporation (NYSEMKT:ALN), Sophiris Bio, Inc. (NASDAQ:SPHS)

Chris Lewis03 mins

On 11 AUG Chimera Investment Corporation (NYSE:CIM) last released its earnings data on Monday. The company reported $0.10 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.09 by $0.01. On average, analysts predict that Chimera Investment Corp. will post $0.39 earnings per share for the current fiscal year. Chimera Investment Corporation…

Read More

Micro-cap Most Volatile Stocks: Amicus Therapeutics (NASDAQ:FOLD), Synthetic Biologics Inc (NYSEMKT:SYN), IsoRay (NYSEMKT:ISR), Ultra Clean (NASDAQ:UCTT)

Jayne Crisman02 mins

According to a report by Reuters on Wednesday, New Jersey-based Amicus Therapeutics Inc. (NASDAQ:FOLD) announced that in a 24-month trial, its new drug migalastat was effective at reducing abnormal fat accumulation in kidney cells compared with placebo. The drug is being considered alone and in combination therapy for treating Fabry disease, a congenital disorder that…

Read More

Micro-cap Gainers: Synthetic Biologics Inc (NYSEMKT:SYN), GTT Communications (NYSEMKT:GTT), Golden Enterprises (NASDAQ:GLDC), NanoViricides (NYSEMKT:NNVC)

Colin Pettis02 mins

The board of directors of Synthetic Biologics, Inc (NYSEMKT:SYN) determined to hold its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2014. The record date, time and location of the Annual Meeting will be as set forth in the Company’s proxy statement for the Annual Meeting. Synthetic Biologics Inc (NYSEMKT:SYN) stock performance…

Read More
FB Nasdaq FB Facebook

Hot BiotecH Stocks: Alnylam Pharmaceuticals (NASDAQ:ALNY), Sangamo Biosciences (NASDAQ:SGMO), Dyax Corp. (NASDAQ:DYAX), Synthetic Biologics Inc (NYSEMKT:SYN)

Kevin Long02 mins

It was the biggest loser on the Bloomberg Massachusetts Index: Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), down more than 12 percent. The Cambridge company is developing a new class of medicines based on RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising approach to silence disease-causing genes, according to its website. Alnylam Pharmaceuticals, Inc….

Read More

Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kristen Barton03 mins

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)…

Read More

Biotech New Highs: EXACT Sciences Corporation (NASDAQ:EXAS), Synthetic Biologics (NYSEMKT:SYN), Amgen (NASDAQ:AMGN), Prothena Corporation (NASDAQ:PRTA)

Kristen Barton02 mins

A colon cancer screening test under development at Madison-based Exact Sciences Corp. (NASDAQ:EXAS) can detect early-stage cancer better than other noninvasive approaches, according to a study published online Wednesday. EXACT Sciences Corporation (NASDAQ:EXAS) stock performance was 0.21% in last session and finished the day at $14.45. Traded volume was 7.74 million shares in the last…

Read More